{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:02:51Z","timestamp":1780358571574,"version":"3.54.1"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T00:00:00Z","timestamp":1410393600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0003144","type":"journal-article","created":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T14:00:34Z","timestamp":1410444034000},"page":"e3144","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Direct Comparison of the Efficacy and Safety of Oral Treatments with Oleylphosphocholine (OlPC) and Miltefosine in a Mouse Model of L. major Cutaneous Leishmaniasis"],"prefix":"10.1371","volume":"8","author":[{"given":"Anny","family":"Fortin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana P.","family":"Caridha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Leed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklyn","family":"Ngundam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenell","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bosschaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandi","family":"Parriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Grogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"F Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"ref2","first-page":"1","article-title":"Control of the leishmaniases","volume":"949","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.idc.2012.03.001","article-title":"Cutaneous and mucocutaneous leishmaniasis","volume":"26","author":"H Goto","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"SL Croft","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"ref6","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"SL Croft","year":"2006","journal-title":"Indian J Med Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"J van Griensven","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"TP Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1093\/jac\/dks273","article-title":"Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis","volume":"67","author":"A Fortin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4269\/ajtmh.11-0812","article-title":"Drug discovery algorithm for cutaneous leishmaniasis","volume":"88","author":"M Grogl","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"ref11","unstructured":"Anonymous (1996) Guide for the care and use of laboratory animals. National Research Council, Washington, DC."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1056\/NEJM199912093412411","article-title":"Miltefosine-the long-awaited therapy for visceral leishmaniasis?","volume":"341","author":"BL Herwaldt","year":"1999","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy-challenges and opportunities","volume":"17","author":"SL Croft","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","article-title":"Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis","volume":"83","author":"I Velez","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.trstmh.2006.02.022","article-title":"Treatment of New World cutaneous leishmaniasis with miltefosine","volume":"100 Suppl 1","author":"J Soto","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00436-013-3638-2","article-title":"First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum","volume":"113","author":"L Hernandez","year":"2014","journal-title":"Parasitol Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa011882","article-title":"Fluconazole for the Treatment of Cutaneous Leishmaniasis Caused by <italic>Leishmania major<\/italic>","volume":"346","author":"AA Alrajhi","year":"2002","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/cid\/cir496","article-title":"High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis","volume":"53","author":"AQ Sousa","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0003144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T15:44:22Z","timestamp":1539963862000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0003144"}},"subtitle":[],"editor":[{"given":"Timothy G.","family":"Geary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,11]]},"references-count":18,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0003144","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,11]]}}}